Microscopic polyangiitis
ORPHA:727DiseaseNot applicableAdult, Childhood
Фенотипы (HPO)55
Очень частый (80–99%)13
HP:0000083Renal insufficiency
HP:0000099Glomerulonephritis
HP:0000790Hematuria
HP:0000988Skin rash
HP:0001945Fever
HP:0002105Hemoptysis
HP:0002633Vasculitis
HP:0002960Autoimmunity
HP:0008653Crescentic glomerulonephritis
HP:0010783Erythema
HP:0012649Increased inflammatory response
HP:0100520Oliguria
HP:0100820Glomerulopathy
Частый (30–79%)22
HP:0001903Anemia
HP:0001933Subcutaneous hemorrhage
HP:0002014Diarrhea
HP:0002017Nausea and vomiting
HP:0002027Abdominal pain
HP:0002239Gastrointestinal hemorrhage
HP:0002586Peritonitis
HP:0002829Arthralgia
HP:0003326Myalgia
HP:0003565Elevated erythrocyte sedimentation rate
HP:0004396Poor appetite
HP:0004936Venous thrombosis
HP:0005244Gastrointestinal infarctions
HP:0012378Fatigue
HP:0012614Abnormal urine cytology
HP:0032018Multiple mononeuropathy
HP:0032230Cytoplasmic antineutrophil antibody positivity
HP:0033505Livedo reticularis
HP:0033557Anti-proteinase 3 antibody positivity
HP:0033559Anti-myeloperoxidase antibody positivity
HP:0034104Anti-neutrophil elastase antibody positivity
HP:0200042Skin ulcer
Периодический (5–29%)20
HP:0000246Sinusitis
HP:0000421Epistaxis
HP:0000554Uveitis
HP:0000965Cutis marmorata
HP:0001369Arthritis
HP:0001482Subcutaneous nodule
HP:0001635Congestive heart failure
HP:0001701Pericarditis
HP:0001733Pancreatitis
HP:0001824Weight loss
HP:0003401Paresthesia
HP:0008046Abnormal retinal vascular morphology
HP:0009830Peripheral neuropathy
HP:0011675Arrhythmia
HP:0025188Retinal vasculitis
HP:0025420Diffuse alveolar hemorrhage
HP:0031363Palpable purpura
HP:0100534Episcleritis
HP:0100749Chest pain
HP:0100758Gangrene
Эпидемиология21
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 1 | Europe | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.26 | Germany | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.2843 | Worldwide | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.16 | Spain | Value and class |
| Point prevalence | 1-9 / 100 000 | 9.4 | Sweden | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.5 | Australia | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.5 | France | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.27 | Norway | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.7 | New Zealand | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.74 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.3 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.8 | Germany | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.91 | Australia | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.38 | Japan | Value and class |
| Annual incidence | 1-9 / 100 000 | 2.4 | Kuwait | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.82 | Japan | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.71 | Canada | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.02 | Greece | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.3 | Lithuania | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.01 | Sweden | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.6 | United States | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)